Clinical Trials on SARS-CoV-2 Infection (Asymptomatic) in Australia

Total 57 results

Murdoch Childrens Research Institute
Rhinomed Pty Ltd

Completed

Diagnosis of Respiratory Viruses in Children With Rhinoswab Junior

COVID-19 | SARS CoV 2 Infection

Australia
Glycovax Pharma Inc.
Government of Canada; JSS Medical Research Inc.; Seppic; Avance Clinical Pty Ltd.

Active, not recruiting

Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults

SARS-CoV-2

Australia
Medical University Innsbruck
Medical University of Graz; Medical University of Vienna

Recruiting

Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2 (HeVacc)

SARS-CoV2 Infection

Austria
University of Melbourne
The George Institute; The University of Queensland; The Peter Doherty Institute... and other collaborators

Recruiting

Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (ASCOT ADAPT)

SARS-CoV-2 Infection (COVID-19)

Australia
Medical University of Vienna

Unknown

Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic. (CONEC)

SARS-CoV 2 | Immunization; Infection

Austria
Medical University Innsbruck

Recruiting

Neurological Outcome After SARS-CoV-2 Infection (ATTRACT)

SARS-CoV-2 | Post-acute COVID-19 Syndrome

Austria
Medical University of Graz

Completed

Survey of Symptoms After a COVID Vaccination in Employees

Symptoms Recoding SARS-CoV-2 After Vaccination

Austria
Medical University of Graz

Terminated

Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines (CoVVacBoost)

Anti-SARS-CoV-2 Antibody Response

Austria
Technovalia, Pty Ltd
Chulalongkorn University; Southern Star Research Pty Ltd.; BioNet-Asia

Active, not recruiting

Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults

COVID-19, SARS CoV 2 Infection

Australia
Memo Therapeutics AG

Completed

To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.

SARS-CoV-2 Infection

Australia
NGM Biopharmaceuticals, Inc

Terminated

A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

SARS-CoV-2 Infection

Australia
Novavax

Completed

Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (COVID-19)

COVID-19 | SARS CoV 2 Infection

Australia
Gilead Sciences

Approved for marketing

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

SARS-CoV2 Infection

United States, Israel, Belgium, Spain, Australia, Denmark, Italy, Germany, France, Portugal, United Kingdom, Poland, Switzerland, Canada, Austria, Cyprus, Czechia, Estonia, Greece, Hungary, Iceland, Ireland, Lithuania, Netherlands, Romania and more
University of Melbourne
London School of Hygiene and Tropical Medicine; The Alfred; University of Adelaide and other collaborators

Recruiting

Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection

Influenza, Human | SARS-CoV-2 Infection

Australia
ACM Biolabs

Completed

Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally.

SARS-CoV-2 Infection

Australia
ModernaTX, Inc.

Recruiting

A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults

SARS-CoV-2

Australia
St. Anna Kinderkrebsforschung

Completed

COVID-19: Infectious Potential of SARS-CoV-2 Intestinal Shedding in Pediatric Patients (INPOSIS) (INPOSIS)

Covid19 | SARS-CoV-2 Infection | Intestinal Infection

Austria
University of Melbourne
Southern Star Research Pty Ltd.

Completed

Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults

SARS-CoV-2

Australia
AUVA
Paracelsus Medical University

Completed

Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.

Coronavirus Infection | SARS-CoV 2 | Covid19 | Severe Acute Respiratory Syndrome Coronavirus 2

Austria
GlaxoSmithKline
CureVac

Active, not recruiting

A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults

SARS-CoV-2

Australia, United States
Kepler University Hospital

Completed

Prediction of Conversion From Vv-ECMO to Va-ECMO in COVID-19 Patients (ECMOPred-vvva)

ARDS Due to Disease Caused by SARS Co-V-2

Austria
Medical University of Vienna

Unknown

Vienna Versus SARS-CoV-2 Virus Study (VIVI)

COVID-19 | SARS-CoV-2

Austria
Medical University Innsbruck

Unknown

Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19

COVID-19 | SARS-CoV 2

Austria
BioNTech SE
Pfizer

Completed

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

COVID-19 | SARS-CoV-2 Infection

Australia, New Zealand
Pfizer

Completed

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

COVID-19 | SARS-CoV-2 Infection

Australia, New Zealand
Novavax

Completed

Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine

Covid19 | SARS-CoV Infection

Australia
ModernaTX, Inc.

Completed

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

Influenza | SARS-CoV-2 | RSV

United Kingdom, Australia, United States
Medical University Innsbruck
Ludwig-Maximilians - University of Munich; Deutsches Zentrum für Herz-Kreislauf-Forschung...

Completed

Stopping ACE-inhibitors in COVID-19 (ACEI-COVID)

COVID-19 | SARS-CoV-2

Germany, Austria
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

COVID-19 | SARS-CoV-2

Australia, United States, Philippines
University of Sydney
Telethon Kids Institute; Bionet Co., Ltd; Technovalia; Institute for Clinical Pathology...

Completed

The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers (COVALIA)

SARS-CoV2 COVID-19

Australia
The University of Queensland
Syneos Health; Coalition for Epidemic Preparedness Innovations

Active, not recruiting

A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

Covid19 | SARS-CoV2

Australia
AstraZeneca

Active, not recruiting

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

COVID-19, SARS-CoV-2

United States, Belgium, Canada, France, Spain, Denmark, Thailand, Vietnam, Korea, Republic of, United Kingdom, Malaysia, Israel, Taiwan, Australia, Germany, Poland, Singapore, United Arab Emirates
Bayside Health
Gilead Sciences; Centre for Clinical Research Excellence in Infectious Diseases...

Unknown

HIV-HBV Co-Infection and Liver Disease

HIV Infections | HIV-HBV Co-Infection

Australia
University of Minnesota
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Recruiting

Respiratory Virus Hospitalization Study (FLU 003 Plus)

Influenza | Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) | Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)

United States, Australia, Spain, Denmark, Greece, Argentina, United Kingdom, Belgium, Chile, Germany, Peru, Thailand
Bayside Health
National Institutes of Health (NIH); Monash Medical Centre

Unknown

Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)

HIV Infections | HIV-hepatitis Co-infection

Australia
University of Chile
Columbia University

Recruiting

The Covid-19 HEalth caRe wOrkErS (HEROES) Study (HEROES)

Depression | Covid-19 | Anxiety | Mental Health Disorder | SARS-CoV-2 | Stress Disorder

United States, Italy, Argentina, Armenia, Australia, Bolivia, Chile, Costa Rica, Czechia, Germany, Guatemala, Lebanon, Mexico, Netherlands, Nigeria, Puerto Rico, Saudi Arabia, Spain, Tunisia, Turkey, Venezuela
The Alfred
Cellestis

Completed

Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals

HIV Infection | CMV Infection

Australia
University of Sydney

Unknown

Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation (R3ACT)

CMV Infection | EBV | Adenovirus

Australia
Medical University of Vienna
Medical Scientific Fund of the Mayor of Vienna

Completed

Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections

Critical Illness | Covid19 | Sars-CoV2 | Viral Infection | Disseminated Intravascular Coagulation | Coagulation Disorder, Blood

Austria
Marinomed Biotech AG

Completed

Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers

COVID-19 | Common Cold | Respiratory Viral Infection | Severe Acute Respiratory Syndrome (SARS) Pneumonia | Corona Virus Disease

Austria
Maastricht University Medical Center
Charles University, Czech Republic; Karolinska University Hospital; Hospices... and other collaborators

Recruiting

European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO (EuroECMO-COVID)

Septic Shock | Extracorporeal Membrane Oxygenation | COVID | SARS-CoV-2 | Cardiogenic Shock | ARDS, Human | Refractory Hypoxemia

Spain, Germany, Netherlands, France, Sweden, Belgium, Austria, Portugal, Poland, United Kingdom, Italy, Lithuania, Czechia, Denmark, Greece, Hungary, Israel, Russian Federation, Switzerland
Merck Sharp & Dohme LLC

Completed

Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)

Cytomegalovirus (CMV) Infection

United States, Australia, Colombia, France, Germany, Israel, Japan, Mexico, Poland, Spain, Turkey
Meridian Bioscience, Inc.

Completed

Detection of Cytomegalovirus Virus in Neonates (CMV)

CMV

United States, Australia, Canada, Italy
Melbourne Health
Peter MacCallum Cancer Centre, Australia; Western Sydney Local Health District and other collaborators

Enrolling by invitation

Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient (CReSCT)

Cytomegalovirus Infections | Immune Suppression | Haematological Malignancy | Organ or Tissue Transplant; Complications

Australia
Starpharma Pty Ltd
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.

HIV Infections | HSV-2 Genital Herpes

Australia
Astellas Pharma Global Development, Inc.
Vical

Completed

A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor

Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients

United States, Australia, Canada, France, Germany, Spain
Medical University of Vienna

Completed

Evaluation of Intestinal Brush Border Enzyme Function in Critically Ill Patients

Critical Illness | Septic Shock | SIRS

Austria
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (HELIOS)

Cytomegalovirus (CMV)-Positive Recipients | Allogeneic, Hematopoietic Cell Transplant (HCT)

Japan, Korea, Republic of, United States, Canada, Australia, Belgium, France, Germany, Spain, Sweden, Taiwan
Merck Sharp & Dohme LLC

Completed

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

Cytomegalovirus (CMV) Infections

United States, Australia, Canada, Finland, Israel, Russian Federation, Spain
Merck Sharp & Dohme LLC

Completed

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

CMV Disease

United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, France, Germany, Hungary, Italy, Mexico, New Zealand, Poland, Spain, United Kingdom

Clinical Trials on SARS-CoV-2 Infection (Asymptomatic) in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations